Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab with Chemoradiation in Head and Neck Cancer
NCT00468169Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Jul 2006
- Primary completion
- Aug 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cetuximab in head and neck cancer (HNC) (2 arms), sponsored by University of Chicago. Primary endpoint: Progression Free Survival at 2 years. Started Jul 2006; status: completed.
02
Drugs
cetuximab
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT00468169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00468169.